BMS signs cancer deal with Exelixis
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbhas acquired the development and commercialisation rights to two of Exelixis's novel small-molecule inhibitors for cancer in a deal that could be worth up to $855 million to the San Francisco-based biotech company.